Safety and Efficacy of 3 Dose Levels of NMD670 in Adult Patients With Myasthenia Gravis (SYNAPSE-MG)
A Phase 2b, Randomised, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of 3 Dose Levels of NMD670 Over 21 Days in Adult Patients With AChR/MuSK-Ab+ Myasthenia Gravis
Sponsor: NMD Pharma A/S
This PHASE2 trial investigates Myasthenia Gravis and Myasthenia Gravis, MuSK and is currently actively recruiting participants. NMD Pharma A/S leads this study, which shows 13 recorded versions since 2024 — indicating substantial longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.
Status Flow
Change History
13 versions recorded-
Mar 2026 — Present [monthly]
Recruiting PHASE2
-
Feb 2026 — Mar 2026 [monthly]
Recruiting PHASE2
-
Dec 2025 — Feb 2026 [monthly]
Recruiting PHASE2
-
Sep 2025 — Dec 2025 [monthly]
Recruiting PHASE2
-
May 2025 — Sep 2025 [monthly]
Recruiting PHASE2
▶ Show 8 earlier versions
-
Mar 2025 — May 2025 [monthly]
Recruiting PHASE2
-
Feb 2025 — Mar 2025 [monthly]
Recruiting PHASE2
-
Dec 2024 — Feb 2025 [monthly]
Recruiting PHASE2
-
Nov 2024 — Dec 2024 [monthly]
Recruiting PHASE2
-
Sep 2024 — Nov 2024 [monthly]
Recruiting PHASE2
-
Aug 2024 — Sep 2024 [monthly]
Recruiting PHASE2
-
Jul 2024 — Aug 2024 [monthly]
Recruiting PHASE2
Status: Not Yet Recruiting → Recruiting
-
Jun 2024 — Jul 2024 [monthly]
Not Yet Recruiting PHASE2
First recorded
May 2024
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- NMD Pharma A/S
For direct contact, visit the study record on ClinicalTrials.gov .
Study Locations
Aarhus, Denmark , Augusta, United States , Aurora, United States , Barcelona, Spain , Belgrade, Serbia , Bergamo, Italy , Boca Raton, United States , Bologna, Italy , Bordeaux, France , Carlsbad, United States and 24 more locations